Humacyte (HUMA) EBT Margin (2020 - 2026)
Humacyte's (HUMA) quarterly EBT Margin came in at 7125.37% in Q2 2026, up 331981.0% year-over-year from N/an in Q2 2025, and down 14.23% quarter-over-quarter from 6237.58% in Q1 2026.
Powered by 
Analysis
Humacyte (HUMA) EBT Margin (2020 - 2026) Analysis & Trends
Humacyte (HUMA) has reported EBT Margin for 4 consecutive years, with 7125.37% the latest figure, recorded in Q2 2026.
- On a quarterly basis, EBT Margin rose 331981.0% year-over-year to 7125.37% in Q2 2026; TTM through Jun 2026 was 5640.88%, a 884372.0% increase from a year earlier, with the FY2025 full-year figure at 5731.11%, changed N/A from the prior year.
- EBT Margin was 7125.37% for Q2 2026 at Humacyte, down from 6237.58% in the prior quarter.
- Over five years, EBT Margin peaked at 3507.57% in Q3 2025 and troughed at 10445.18% in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.21 Bn | 9.36 Bn | 112.79 Mn | 55.43% |
| 2 | CRISPR Therapeutics AG | 5.02 Bn | 5.02 Bn | - | -885.91% |
| 3 | Iovance Biotherapeutics | 3.64 Bn | 3.34 Bn | 55.72 Mn | -49.02% |
| 4 | Legend Biotech | 3.53 Bn | 2.57 Bn | 251.50 Mn | 14.32% |
| 5 | uniQure | 2.98 Bn | 2.98 Bn | 5.49 Mn | -1,356.24% |
| 6 | Beam Therapeutics | 2.53 Bn | 2.53 Bn | - | -24,299.18% |
| 7 | Precigen | 2.39 Bn | 2.39 Bn | 52.17 Mn | 36.51% |
| 8 | Sarepta Therapeutics | 2.15 Bn | 1.35 Bn | 251.87 Mn | -0.44% |
| 9 | Vericel | 1.93 Bn | 1.76 Bn | 56.40 Mn | 2.88% |
| 10 | Humacyte | 133.72 Mn | 133.72 Mn | -825,000.00 | -7,125.37% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -7,125.37% |
| Mar 31, 2026 | -6,237.58% |
| Dec 31, 2025 | -7,157.60% |
| Sep 30, 2025 | -3,507.57% |
| Jun 30, 2025 | -10,445.18% |
| Mar 31, 2025 | -4,939.65% |
| Sep 30, 2021 | -13,096.68% |
| Sep 30, 2020 | -1,943.11% |